Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has submitted a corrected disclosure for its Annual General Meeting of Shareholders scheduled for March 15, 2024, adding agenda items for the new appointment of Seung-Hwan Suh as Outside Director and Audit Committee Member.
📊 [Key Disclosure Details & Financial Figures]
- Reason for Correction: Addition of agenda items for the General Meeting of Shareholders
- Correction Filing Date: February 21, 2024 (Initial Filing Date: February 14, 2024)
- Meeting Type: 13th Annual General Meeting of Shareholders
- Date & Time: March 15, 2024, at 09:00 KST
- Location: Room 113, 1st Floor, Songdo Convensia (123 Central-ro, Yeonsu-gu, Incheon)
- Agenda Items:
- Report Items: Report on Transactions with Related Parties, Audit Report, Business Report, Report on the Operational Status of Internal Accounting Control System
- Voting Items (Post-Correction):
- Item 1: Approval of Financial Statements for the 13th Fiscal Year (2023.01.01 ~ 12.31)
- Item 2: Appointment of Outside Director (Seung-Hwan Suh) (New Appointment – Added)
- Item 3: Appointment of Audit Committee Member (Seung-Hwan Suh) (New Appointment – Added)
- Item 4: Approval of Limit on Remuneration for Directors
- Newly Nominated Candidate Details:
- Seung-Hwan Suh (Candidate for Outside Director and Audit Committee Member, 3-year term, Born June 1956, Former Minister of Land, Infrastructure and Transport and Former President of Yonsei University)
- Board Resolution Date: February 14, 2024 (4 Outside Directors attended, 0 absent)
- Other Remarks: Details are subject to change based on corporate circumstances
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Shareholder Approval of Added Agenda Items and Subsequent Board Structure Changes
This correction disclosure reports the addition of new agenda items for the upcoming Annual General Meeting, specifically nominating Seung-Hwan Suh as Outside Director and Audit Committee Member. Tracking whether these added proposals gain approval during the general meeting is essential to understand subsequent changes in board composition. Investors can verify the final voting outcomes through the ‘Results of General Meeting of Shareholders’ disclosure following the meeting.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
